Condition
Biliary Tract Tumor
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Unknown2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06048289UnknownPrimary
Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy
NCT05291052Phase 2UnknownPrimary
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
NCT04707365Not ApplicableNot Yet Recruiting
Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort
Showing all 3 trials